温尼伯大亚愽国际app下载学

消息

研究

新的癌症筛查测试可以挽救生命

Anuraag Shrivastav博士开发了一种新型的血液检查,可检测癌前病变和结直肠癌

UWinnipeg’s Dr. Anuraag Shrivastav has created a novel blood test that detects precancerous lesions and colorectal cancer.

尽管是世界上最可预防的癌症之一,但大肠癌是男性的第三个致命,第二个是女性。

Anuraag Shrivastav博士温尼伯大学生物学系教授,希望通过创建新的筛查测试来降低死亡率,以较早发现结直肠癌。亚愽国际app下载Shrivastav已经进行了15年以上的癌症研究,包括creating a test to improve the treatment odds of patients diagnosed with breast cancer.

In our small clinical trial, which we just completed, we found that this test is highly sensitive and specific to not just colorectal cancer, but early stages of colorectal cancer.

Anuraag Shrivastav博士

他解释说:“癌症的潜在生物学是设计测试和疗法的重要方面。”“如果结直肠癌在早期被诊断出来,这是可以预防的,并且是少数接受筛查测试的癌症之一。”

但是,他说的问题是,加拿大目前的筛查测试“非常不愉快”,因为这是一项粪便测试。科学名称是Guaiac粪便隐匿血液测试(GFOBT)。

为了创造更有效和患者友好的测试,Shrivastav和他的团队开发了一种新型的血液检查,可检测到癌前病变和结直肠癌。在一项小型概念验证研究中,该测试在检测癌前病变方面非常敏感,超过了目前市场上其他市场上其他非侵入性大肠癌筛查测试。

“It can easily be incorporated into your annual bloodwork,” Shrivastav explained. “In our small clinical trial, which we just completed, we found that this test is highly sensitive and specific to not just colorectal cancer, but early stages of colorectal cancer.”

防止结直肠癌

加拿大癌症协会建议患有大肠癌的平均风险的人开始参加50岁的常规粪便测试。

Shrivastav says that this is typically the age when individuals start getting polyps in the GI tract, which are abnormal tissue growths in the colon and rectum. While not all polyps are dangerous and not all develop into cancer, certain polyps can be precancerous.

他解释说:“这些息肉可以转化为结直肠癌,但几乎需要五到十年。”“想象一下我们在这里拥有的机会之窗。在此期间,您可以通过结肠镜检查去除这些息肉并预防结直肠癌。那是巨大的。”

通过这种新的筛选试验,如果病人测试s positive following blood work, they are then sent to get a colonoscopy and have medical professionals physically look at and remove all of the polyps.

这有两个主要好处。首先是早期检测可防止结直肠癌。第二个是因为GFOBT会产生许多误报,而血液检查不会。

“If you are detecting it early, the health care costs are low. For example, Stage 1 colorectal cancer treatment costs approximately $25,000 to the Canadian health care system,” he explained. “It’s approximately $75,000 if Stage 4. So, it does not only improve the quality of life, but it also brings down the cost for the health care system.”

另一个积极的是,可能患有该疾病家族史的年轻高危患者可以开始在生命的早期就可以轻松地进行测试。

Student research key

研究生Abinash Meher

Shrivastav表示,如果没有他的临床合作者Harminder Singh博士,这项研究是不可能的,他是健康科学中心和曼尼托巴大学的曼尼托巴省研究人员的共同申请人。

几位大学生和毕业生Uwinnipeg的学生在最初的研究中也发挥了重要作用,并将研究提高到了这一点。

Shiv Bhanot,Jenny Rathinagopal和Jordan Min以前曾与Shrivastav和他的现任研究生Abinash Meher合作,是从事该项目的关键实验室人员之一。

An international student from India, Meher says learning from Shrivastav has been a rewarding experience, as has been the research he’s undertaken.

“我真的很想帮助社会,”梅赫说。“我们可以看到癌症是如何在世界范围内传播的,如果您问一个随机的人,他们会认识一生中有癌症的人。”

前进商业化

Thanks to a $261,000 Research Manitoba Innovation Proof-of-Concept Grant, Shrivastav and his team will be conducting a study to validate the test. The original proof-of-concept study included 74 patients, but now they are planning a confirmatory trial of 650 patients with industry partner VastCon, who is developing the test and is interested in taking it to the market.

他解释说:“确认性试验可以通过基本显示测试的有效性将我们提升到一个新的水平。”“下一步将在关键试验后将测试带入市场。”

在美国,Shrivastav说,确切科学的另一项筛查测试称为Cologuard,他称其为“盒子中的便便”,其功效比GFOBT更好。

精确的科学与辉瑞公司合作创造了结直肠筛查的空间。拟议的临床研究的积极结果将为与大型制药公司合作开放,以将测试推向市场。

“研究后,如果一切顺利,就不应花费超过三到四年的时间将测试进入市场。”

媒体联系

Baidu